Accuray Continues Global Expansion in South Asia and Announces the First Two CyberKnife® VSI™
NOVEMBER 20, 2012 10:00 PM EST
SUNNYVALE, California, Nov. 21, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Medanta - The Medicity Cancer Institute, and the Roentgen-BLK Super Speciality Hospital both recently acquired and started treating patients with the CyberKnife® VSI™ System the premier solution for full-body radiosurgery marking the first-in-country CyberKnife VSI Systems in India.
Cancer incidence is growing in India with 900,000 new cancer cases and 400,000 cancer deaths annually. Cancers account for eight percent of total deaths in India thus creating a larger demand for cancer treatments.
By enriching their therapeutic offerings in radiation oncology, Medanta - The Medicity Cancer Institute and the Roentgen-BLK Radiation Oncology Center can now provide patients treatment with the CyberKnife System and expand the patient population that can now benefit from CyberKnife radiosurgery and stereotactic body radiation therapy (SBRT) in the region.
"The CyberKnife System is increasingly being used as an alternative to conventional radiation therapy in situations where its targeting accuracy allows a shorter and more intense course of radiation, including radiosurgery for brain tumors. We are pleased to have introduced this innovative technology at Medanta and look forward to witnessing the benefits that the System offers, including real-time tracking with automatic correction of tumors that move throughout the body. The CyberKnife System comes as a significant development in cancer therapy for patients as well as doctors as it offer the most precise treatment option for a wide range of patients," said Naresh Trehan, M.D., Chairman and Managing Director of Medanta - The Medicity.
"We are always refining radiation oncology treatment methods to deliver the highest-quality patient care possible, while working to also reduce or eliminate the side effects that accompany radiation treatment. Using the CyberKnife System allows our radiation oncologists to provide the most up-to-date technology available to accurately target tumors, deliver treatments with pinpoint accuracy and ensure that tumors get the most effective ablative dose while healthy tissues and critical structures are spared," said Praneet Kumar, M.D., CEO of Roentgen-BLK Radiation Oncology Center.
Building upon the foundation of accuracy and precision in radiosurgery, the CyberKnife System extends these benefits to fractionated high precision radiation therapy with robotic intensity-modulated radiotherapy (IMRT) that can be delivered anywhere in the body, including intracranial, head and neck, spine, lung, liver and prostate. The enhanced spectrum of treatment options allows for more customized treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated area, or patients requiring partial breast irradiation. With more than 700 hundred peer-reviewed publications and a rapidly increasing number of treated patients, the growing community of CyberKnife users is discovering more applications that can be helped by the technological edge that the CyberKnife System provides.